CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company ...

Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only ... Source: FactSet Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only ... Source: FactSet Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to ...

Shares of Altimmune, Inc. climbed early on Thursday, recovering from a nearly 6% drop in the previous session, drawing ...

Alvotech ( (ALVO) ) just unveiled an announcement.

today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective ...

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical ...

Spyre Therapeutics (SYRE) announced Spyre has been added to the Nasdaq Biotechnology Index effective prior to market open, Monday, December 23.

has been selected to join the Nasdaq Biotechnology Index (NBI). The inclusion will be effective from the start of trading on December 23, 2024. The company, currently valued at approximately $530 ...

today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed.

will be included in the Nasdaq Biotechnology Index (NASDAQ:NBI) starting Monday, December 23, 2024. Despite an 8% decline over the past week, the stock has shown resilience with a 34% gain over ...